A Case of a Durable Partial Response to Late‐Line Axitinib Following Prior Use of Tyrosine Kinase Inhibitors in Metastatic Papillary Renal Cell Carcinoma
Late-sequence treatment with axitinib following prior use of tyrosine kinase inhibitor therapy resulted in a long-term response in a patient with metastatic papillary renal cell carcinoma.
Authors
- Eigo Kuribayashi
- Naoto Hodotsuka (ORCID: https://orcid.org/0000-0002-9796-9621)
- Yuichiro Honda (ORCID: https://orcid.org/0000-0002-8664-475X)
- Yasutomo Suzuki (ORCID: https://orcid.org/0000-0001-5732-5779)
- Shuma Endo
- Kyota Suzuki
- Shohei Yamaki
- Yukihiro Kondo
Institutions
- Nippon Medical School Hospital (JP)
- Chiba Hokusou Hospital (JP)
Publication Details
- Journal
- IJU Case Reports
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1002/iju5.70115
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00